

PRESS RELEASE

Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference

Lund, Sweden, 19 December 19, 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Hansa CEO Renée Aguiar-Lucander will be presenting at J.P. Morgan's 44th Annual Healthcare Conference at 10:30 AM PST, Georgian, Weston St. Francis, in San Francisco, California. The conference runs from Monday 12 January to Thursday 15 January and will also be attended by CFO Evan Ballantyne, COO Maria Törnsén, CMO Richard Philipson and CLO Brian Gorman.

The J.P. Morgan Healthcare Conference is a major healthcare investment symposium in the industry, which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

For the opportunity to meet with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com, or register at [LifeSci Partners Corporate Access Event 2026](#) for in-person 1 on 1 meetings at the Beacon Grand Hotel a block away from the J.P. Morgan Conference.

Event: J.P. Morgan's 44th Annual Healthcare Conference, Hansa Biopharma Presentation

Webcast Link: [Webcast - 44th Annual J.P. Morgan Healthcare Conference](#)

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Time: 10:30 AM PST

Date: Wednesday 14 January, 2026

Place: Georgian, Weston St. Francis, San Francisco, California

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme

technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on [LinkedIn](#).

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.